Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.


TSX:ACB - Post by User

Comment by Rotalucepson Sep 20, 2022 8:32pm
220 Views
Post# 34975223

RE:The report isn't bad at all

RE:The report isn't bad at all
quinlash wrote: They increased sales, slipped a little on margin however the margins they are reporting are way higher than recreational cannabis margins.  One time write-downs / expenses would need to be reviewed by all to see what makes that up however the company is making moves to optimize operations etc so it shouldn't come as a big surprise.  EBITDA timeline looks very promising assuming the company excutes properly on their plans.

Anyhow, that's my feedback after a quick review of the report

DYODD / GLTA

Q


You said it, ACB is stalling or declining like all the others. How will ACB grow with the competition? The population will double? ACB will launch a new product already produce by the competition? So they promise peanuts and you are all excited?  If ACB reach its goal to be EBITDA at the end of 2022, it would be a first in the whole sector since they all failed on their promise. Only the naive would believe this. Then EBITDA? No, "ajusted EBITDA" and you know the meaning.  Even the private companies, well managed are struggling too, too much competition.

PS; quinpump is a pumper. He lured the naive Hexo investors from $14.00 to .26c. 
<< Previous
Bullboard Posts
Next >>